2024 ASCO® Annual Meeting

The 2024 American Society of Clinical Oncology Annual Meeting was held May 31-June 4 in Chicago, Illinois and featured over 200 sessions complementing the theme, “The Art and Science of Cancer Care: From Comfort to Cure.”

Guillermo Garcia-Manero, MD, Shares Latest Luspatercept Findings for MDS, Anemia

Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.

Dr. Oluwole on Long-Term Brexu-Cel Outcomes in ZUMA-3

Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.

PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma

Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.

Dr. Kamdar Shares Liso-Cel Data From TRANSCEND-MCL Study

The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.

What Is the Impact of JAK2 Allele Burden in Patients With Myelofibrosis?

Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.

New Fusion Protein Effective, Safe in First-Line MDS therapy

A phase II study evaluated a combination of the IMM01 fusion protein with azacitidine in untreated MDS.

Oral-Route HMAs Carry Less Time Burden in MDS Care

A database analysis compares how much time patients spend in healthcare settings, based on receiving oral, IV, or SC HMAs.

What Is the Benefit of Rituximab Maintenance in Patients With MCL?

After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.

Areej El-Jawahri, MD, Highlights Exciting ASCO Sessions

Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care.

Network Meta-Analysis Compares Efficacy of BTK Inhibitors for CLL

The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.

Fateeha Furqan, MD, Discusses Pirtobrutinib Plus CAR-T

Dr. Furqan shared data from a retrospective analysis on patients who received pirtobrutinib prior to CAR T-cell therapy.

Study Links Factors to Early Severe Hematotoxicity After CAR-T Infusion

Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.

Liso-Cel in B-Cell Lymphomas in TRANSFORM Study With Dr. Kamdar

Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.

Study Suggests Link Between Complement, ICANS in B-Cell Non-Hodgkin Lymphomas

A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T.

Lakshmi Nayak, MD, Shares Pilot Data on Axi-Cel in CNS Lymphoma

These findings concern axi-cel use in relapsed and refractory primary and secondary disease.

Luciano Costa, MD, Discusses Results From CARTITUDE-4 Subanalysis

Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.

Liso-Cel NCP Shows Safety, ‘Clinical Benefit’ in Patients With LBCL

Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.

Emavusertib Reduces Bone Marrow Blasts in Patients With FLT3-Mutated AML

Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.

Guillermo Garcia-Manero, MD, on the Phase II ASTREON Trial

Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.